Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of miR-30 family inhibitor in preparation of medicament for preventing and treating acute myocardial infarction

An acute myocardial infarction, 1.mir-30 technology, applied in small nucleic acid drugs miR-30 family inhibitors, preparation of drugs for the prevention and treatment of acute myocardial infarction, small nucleic acid drugs, can solve the problem that has not been reported, the relationship is unclear, etc. question

Inactive Publication Date: 2015-06-03
FUDAN UNIV
View PDF1 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Although miRNAs and H 2 Both S are involved in the protective effect of myocardial ischemia, but miRNAs and H 2 The relationship between S is currently unclear
In particular, miRNAs regulate H 2 The role of S in acute myocardial infarction has not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of miR-30 family inhibitor in preparation of medicament for preventing and treating acute myocardial infarction
  • Application of miR-30 family inhibitor in preparation of medicament for preventing and treating acute myocardial infarction
  • Application of miR-30 family inhibitor in preparation of medicament for preventing and treating acute myocardial infarction

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] Protective effect of miR-30 family inhibitors on primary cardiomyocyte injury induced by ischemia and hypoxia

[0030] Isolate primary neonatal mouse cells in 5×10 5 The density of cell / ml was inoculated in a 6-well plate, so that the cells reached a confluence rate of 70% to 80%, and transfected with X-tremeGENE siRNA transfection reagent. After 48 hours, real time RT-PCR and Western blot were used to measure CSE The expression levels of mRNA and protein, while detecting H in the cell supernatant 2 S content. In addition, 48 hours after transfection, hypoxia treatment was performed for 8 hours in a hypoxic incubator, and cell viability and apoptosis were detected by MTT and TUNEL. The experimental data were analyzed by one-way analysis of variance, p2 The production of S, and miR-30 family inhibitors can increase the cell viability after ischemia and hypoxia, and reduce the apoptosis caused by ischemia and hypoxia.

[0031] The experimental results proved that miR-3...

Embodiment 2

[0032] Example 2 Protective effect of miR-30 family inhibitors on mouse myocardial infarction model

[0033] The miR-30 family inhibitor was injected into the mice by tail vein injection, and the injection was continued for 3 days. Two hours after the last injection, the mouse model of myocardial infarction was established by ligating the left anterior descending coronary artery, and the operation was 48 Hours later, the expression of CSE in the heart and H in plasma were detected 2 The change of S, the concentrations of myocardial infarction markers LDH, CK and cTnI were detected, the infarct area was calculated by double staining with TTC and Evans blue, and the apoptosis of cells in the infarct border area and the expression of related apoptotic proteins were detected by TUNEL. Ultrasound testing of heart function. The results showed that, compared with the myocardial infarction model group, miR-30 family inhibitors could significantly increase the expression of CSE in the...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of small nucleic acid medicament pharmacy, and relates to an application of a miR-30 family inhibitor in preparation of a medicament for preventing and treating acute myocardial infarction. The results of experimental studies using an in vitro ischemic and anoxic cell model and an in vivo myocardial infarction model show that the miR-30 family inhibitor increases the generation of H2S by increasing expression of cystathionine-gamma-lyase (CSE), thereby protecting in vitro cell damages caused by ischemia and hypoxia, protecting mouse acute myocardial infarction damages caused by ligation of coronary arteries, and determining that the miR-30 family inhibitor has an obvious protective action on myocardial damages caused by ischemia and hypoxia. The miR-30 family inhibitor can be used as a new medicament for protecting damages of acute myocardial infarction.

Description

technical field [0001] The invention belongs to the field of pharmacy and relates to small nucleic acid drugs, in particular to the use of small nucleic acid drug miR-30 family inhibitors in the preparation of drugs for the prevention and treatment of acute myocardial infarction. Background technique [0002] It is disclosed in the prior art that myocardial infarction refers to a sharp reduction or interruption of blood flow in the coronary arteries, resulting in severe and persistent acute ischemia in the corresponding myocardium, eventually leading to a series of changes in cases. In current clinical practice, the best treatment for ischemic heart disease is revascularization plus drug therapy, but practice has shown that percutaneous coronary intervention (PCI) has a risk of in-stent restenosis, and coronary artery bypass grafting has a risk of in-stent restenosis. Possibility of graft occlusion. Therefore, in-depth exploration of the mechanism of ischemic heart disease,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K48/00A61P9/10
Inventor 朱依谆沈亚琪
Owner FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com